reviewed april 2026|next review october 2026|88 physicians psi has verified|17 published studies
Pentagastrin
Pentagastrin is a synthetic pentapeptide containing the C-terminal tetrapeptide sequence of gastrin, previously FDA-approved as Peptavlon for diagnostic gastric acid secretion testing and used for calcitonin provocation testing in medullary thyroid carcinoma (MTC) screening.
Evidence landscape: 17 published studies
Over 5,100 published studies spanning gastric physiology, thyroid cancer diagnostics, and GI pharmacology. Decades of clinical use.
- 5 Human
- 11 Animal
- 1 Reviews
Previously FDA-approved as Peptavlon for diagnostic use. Currently discontinued in the United States. Still available in some international markets for diagnostic purposes.
Discontinued in the US market. Available in some international markets. Used in controlled clinical settings under medical supervision. Not a therapeutic agent.
Pentagastrin is a diagnostic tool, not a treatment. It stimulates gastric acid secretion through CCK2/gastrin receptor activation and calcitonin release from thyroid C-cells. The pentagastrin stimulation test was the historical gold standard for measuring gastric acid output. Calcitonin provocation testing for MTC remains clinically relevant.
PSI Assessment
Some peptides matter not as treatments but as diagnostic tools that reveal how the body works. Pentagastrin is one of them. It mimics gastrin, the hormone that tells the stomach to produce acid, and physicians have used it for decades to test gastric acid secretion and to provoke calcitonin release for thyroid cancer screening. Previously FDA-approved as Peptavlon, it has been discontinued in the US but remains available in some international markets. With over 5,100 published studies, pentagastrin is one of the most thoroughly characterized diagnostic peptides. Its clinical role has narrowed as alternative methods (endoscopic techniques, serum biomarkers, genetic testing) have emerged.
Diagnostic peptide, not a treatment. Previously FDA-approved as Peptavlon. Historical gold standard for gastric acid testing. Calcitonin provocation for thyroid cancer screening. Clinical role narrowing.
The mechanism involves CCK2 (gastrin) receptor activation on gastric parietal cells, stimulating H+/K+ ATPase-mediated hydrochloric acid secretion via phospholipase C, IP3, and calcium signaling. Pentagastrin also stimulates calcitonin release from thyroid C-cells, which is the basis for provocation testing in medullary thyroid carcinoma. An exaggerated calcitonin response indicates C-cell hyperplasia or MTC.
What the evidence supports
Pentagastrin reliably stimulates gastric acid secretion and calcitonin release through CCK2/gastrin receptor activation. Decades of diagnostic use validate the pharmacological profile. The pentagastrin stimulation test was the historical gold standard for measuring gastric acid output. Calcitonin provocation testing for medullary thyroid carcinoma (MTC) screening remains clinically relevant. Previously FDA-approved as Peptavlon for diagnostic use.
What is not yet established
Therapeutic applications beyond diagnostics. Whether pentagastrin-stimulated calcitonin testing remains the preferred approach given advances in genetic RET mutation testing for familial MTC. Whether pentagastrin will return to US clinical availability after discontinuation. The clinical role has narrowed with alternative diagnostic methods.
Research Evidence
The findings below cover the gastric acid testing application, the calcitonin provocation for MTC screening, and the evolving diagnostic landscape.
Evidence by condition
Evidence dimensions across gastric acid testing, MTC screening, and gastric physiology research. Diagnostic applications have the deepest evidence.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Gastric Acid Testing | ||||
| MTC Screening (Calcitonin Provocation) | ||||
| Gastrin Biology Research |
The pentagastrin stimulation test was the historical gold standard for measuring gastric acid output, used to diagnose Zollinger-Ellison syndrome, evaluate acid-suppressive therapy effectiveness, and characterize achlorhydria.
This test measured peak and basal acid output by collecting gastric secretions after subcutaneous pentagastrin injection. Availability has declined as endoscopic and serum biomarker methods have partially replaced direct acid secretion testing.
Intravenous pentagastrin provokes calcitonin release from thyroid C-cells. An exaggerated response is diagnostic for C-cell hyperplasia or medullary thyroid carcinoma (MTC).
Calcitonin provocation testing remains clinically relevant, particularly in countries where pentagastrin is still available. Genetic testing for RET mutations has become the primary screening tool for familial MTC, partially but not completely replacing provocative testing.
Pentagastrin has been used as a standard research tool for studying gastric acid regulation, Helicobacter pylori effects on acid secretion, and proton pump inhibitor pharmacology across thousands of published studies.
The research tool application has been the most enduring use. Pentagastrin remains valuable in gastric physiology research even as its clinical diagnostic role has narrowed.
5 Human|11 Animal|1 Reviews
View all 17 indexed studiesHow Pentagastrin Works
Pentagastrin is a synthetic analog of the C-terminal tetrapeptide of gastrin. It activates CCK2/gastrin receptors on parietal cells (stimulating acid secretion) and thyroid C-cells (stimulating calcitonin release).
Pentagastrin tells the stomach to produce acid, mimicking the same signal the body sends when food is eaten. Physicians use this to test whether the stomach is producing the right amount of acid, or to stimulate calcitonin release for thyroid cancer screening.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Pentagastrin is a synthetic analog of the C-terminal tetrapeptide of gastrin. It binds CCK2/gastrin receptors on parietal cells, stimulating H+/K+-ATPase activity and HCl secretion. It also stimulates calcitonin release from thyroid C cells, which is used in provocative testing for medullary thyroid carcinoma.
What is Pentagastrin being studied for?
Researchers are studying Pentagastrin across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Pentagastrin overall. This means a compound can have human studies for one condition but only animal data for another.
Gastric Acid Testing
·FDA ApprovedPreviously FDA-approved as Peptavlon for diagnostic gastric acid secretion testing. Historical gold standard for measuring peak and basal acid output. Used to diagnose Zollinger-Ellison syndrome and characterize acid secretory status.
Limitations: Discontinued in the US market. Availability has declined globally as endoscopic and serum biomarker methods have partially replaced direct acid secretion testing.
MTC Screening (Calcitonin Provocation)
·Human TrialsPentagastrin provokes calcitonin release from thyroid C-cells. Exaggerated response indicates C-cell hyperplasia or medullary thyroid carcinoma. Remains clinically relevant in markets where pentagastrin is available.
Limitations: Genetic testing for RET mutations has become the primary screening tool for familial MTC, partially replacing provocative testing. Pentagastrin availability limits this application in some markets.
Gastrin Biology Research
·Animal StudiesStandard research tool for studying gastric acid regulation, H. pylori effects, and proton pump inhibitor pharmacology. Used in thousands of published studies.
Limitations: Research tool application rather than therapeutic or diagnostic advancement. The compound is well-characterized but new scientific insights from pentagastrin studies are incremental.
Safety and Regulatory Status
FDA Status: Previously FDA-approved as Peptavlon for diagnostic use. Currently discontinued in the United States. Available in some international markets.
Availability: Discontinued in US market. Available in some international markets for diagnostic purposes. Administered under medical supervision in controlled clinical settings.
Class context: Transient side effects include abdominal cramping, nausea, and flushing, which are expected effects of gastric acid stimulation and resolve quickly. Administered in controlled clinical settings. Decades of diagnostic use provide extensive safety data.
Pentagastrin is a diagnostic agent with well-known transient side effects (abdominal cramping, nausea, flushing) that are expected from gastric acid stimulation and resolve quickly. Administered under medical supervision.
Questions and Comparisons
Questions the evidence raises for a Pentagastrin discussion.
Comparison and Related Research
Pentagastrin is compared with other diagnostic peptides and GI-active compounds.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Clinical study using pentagastrin stimulation testing to measure maximal gastric acid output in patients stratified by age and presence of gastritis. The pentagastrin stimulation test became a standard clinical tool for diagnosing hypochlorhydria and evaluating gastric secretory capacity, used widely in gastroenterology for decades.Feldman M et al., 1979 in N Engl J Med. View on PubMed
- 2.Clinical study establishing pentagastrin as a pharmacological challenge agent for panic disorder research. Intravenous pentagastrin reliably provoked panic attacks in patients with panic disorder at rates significantly higher than in healthy controls, providing researchers with a controlled method to study panic physiology in the laboratory.Bradwejn J et al., 1991 in Arch Gen Psychiatry. View on PubMed
- 3.Neuroendocrine study showing that pentagastrin infusion activates the hypothalamic-pituitary-adrenal (HPA) axis in healthy subjects and patients with panic disorder. Cortisol and ACTH responses to pentagastrin were used to probe stress response dysregulation, revealing differences in HPA axis reactivity between panic patients and controls.Abelson JL et al., 2005 in Psychoneuroendocrinology. View on PubMed
- 4.Clinical study measuring both acid secretion and serum gastrin responses to pentagastrin in duodenal ulcer patients compared to healthy volunteers. Ulcer patients showed enhanced acid output per unit of pentagastrin dose and altered gastrin kinetics, helping to characterize the hypersecretory phenotype underlying ulcer disease.Lam SK et al., 1995 in Gut. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.